Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus

American Journal of Managed Care

Volumn 8, Issue 16 SUPPL., 2002, Pages

  Kudzma, David J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBUMIN; BIGUANIDE; GLIBENCLAMIDE; GLUCOSE; INSULIN; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE;

ARTERY INTIMA; ARTERY MEDIA; ATHEROSCLEROSIS; B LYMPHOCYTE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; CELL MIGRATION; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DYSLIPIDEMIA; ENDOTHELIUM CELL; EVIDENCE BASED MEDICINE; FIBRINOLYSIS; GLUCOSE TOLERANCE; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LYMPHOCYTE FUNCTION; MICROALBUMINURIA; MICROVASCULARIZATION; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION; VASCULAR DISEASE;

DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; THIAZOLES; THIAZOLIDINEDIONES; UNITED STATES;

EID: 0036806566     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care. 1992;15:318-368.
2. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Rev. 1999;7:139-153.
3. Finegood DT, McArthur MD, Kojwang D, et al. β-cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes. 2001;50:1021-1029.
4. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract. 1998;40(suppl):S21-S25.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
6. UK Prospective Diabetes Study (UKPS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
7. Bell DSH, Overalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus [abstract]. Diabetes. 2001;50(suppl 2):A106.
8. Ovalle F, Bell DS. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2002;4:56-59.
9. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661-1669.
10. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 2001;134:61-71.
11. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 1992;15:193-203.
12. Inzucchi SE, Maggs DG, Spollett GT, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998;338:867-872.
13. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550-554.
14. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360-372.
15. O'Meara NM, Sturis J, Van Cauter E, Polonsky KS. Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus. J Clin Invest. 1993;92:262-271.
16. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest. 1997;100:530-537.
17. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D Jr. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia. 1987;30:698-702.
18. Porter LE, Free MI, Jones NP, Biswas N. Rosiglitazone reduces proinsulin/insulin ratio and improves β-cell function in type 2 diabetes [abstract]. Diabetologia. 2000;43(suppl 1):A192.
19. Zinman B. PPAR gamma agonists in type 2 diabetes: how far have we come in preventing the inevitable? A review of the metabolic effects of rosiglitazone. Diabetes Obes Metab. 2001;3(suppl 1):S34-S43.
20. Prigeon RL, Kahn SE, Porte D Jr. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 1998;83:81-823.
21. Koyama K, Chen G, Lee Y, Unger RH. Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. Am J Physiol. 1997;273:E708-E713.
22. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH. Beta-cell in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci USA. 1994;91:10878-10882.
23. Finegood DT, McArthur MD, Kojwang D, et al. β-cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes. 2001;50:1021-1029.
24. Shimabukuro M, Zhou YT, Lee Y, Unger RH. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem. 1996;273:3547-3550.
25. Bakris G., Weston WM, Rappaport EB, Freed MI. Rosiglitazone produces long-term reductions in urinary albumin excretion in type 2 diabetes. Diabetologia. 1999;42(suppl 1):A230.
26. Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications. 2000;14:250-254.
27. Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care. 1998;21:2135-2139.
28. Despres JP, Lamarche B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
29. Cominacini L, Garbin U, Fratta Pasini AF, et al. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes. 1998;47:130-133.
30. Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM: the Troglitazone Study. Diabetes. 1997;46:433-439.
31. Tack CJ, Smits P, Demacker PN, Stalenhoef AF. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care. 1998;21:796-799.
32. Winkler K, Friedrich I, Nauck M, Wieland H, Maerz W. Pioglitazone reduces dense LDL-particles in patients with type-2 diabetes [abstract]. Diabetes. 2001;50(suppl 2):A147.
33. Brunzell J, Cohen BR, Kreider M, et al. Rosiglitazone favorably affects LDL-C and HDL-C heterogeneity in type 2 diabetes [abstract]. Diabetes. 2001;50(suppl 2):A141.
34. Bakris GL, Dole JF, Porter LE, Huang C, Freed MI. Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus [abstract]. Diabetes. 2000;49(suppl 1):A96.
35. Scherbaum W, Göke B, for the German Pioglitazone Study Group. Pioglitazone reduces blood pressure in patients with type-2-diabetes mellitus [abstract]. Diabetes. 2001;50(suppl 2):A462.
36. Davidson MB. Clinical implications of insulin resistance syndromes. Am J Med. 1995;99:420-426.
37. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:2108-2116.
38. Freed M, Fuell D, Menci L, Heise M, Goldstein B. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes. Diabetologia. 2000;43(suppl 1):A267.
39. Orie NN, Zidek W, Tepel M. Increased intracellular generation of reactive oxygen species in mononuclear leukocytes from patients with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes. 2000;108:175-180.
40. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280:E745-E751.
41. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40:1286-1292.
42. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007-2011.
43. Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes. 2001;50:2384-2389.
44. phox subunit expression in mononuclear cells, and reduces C reactive protein and monocyte chemotactic protein-1: evidence of a potent anti-inflammatory effect [abstract]. Diabetes. 2001;50(suppl 2):A68.
45. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr, for the Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340:14-22.
46. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998;83:1818-1820.
47. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 2001;86:3452-3456.
48. Takagi T, Yoshida K, Akasaka T, Hozumi T, Yamamuro A, Morioka S. Troglitazone reduces intimal hyperplasia after coronary stent implantation in patients with type 2 diabetes mellitus: a serial intravascular ultrasound study [abstract]. J Am Coll Cardiol. 1999;33(2, suppl A):100A-101A.
49. Takagi T, Yamamuro A, Tamita K, et al. Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol. 2002;89:318-322.
50. Yue T, Chen J, Bao W, et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation. 2001;104:2588-2594.
51. Murakami T, Ohnaka M. Effects of insulin resistance and thiazolidinediones on effort-induced angina pectoris with type 2 diabetes mellitus [abstract]. J Am Coll Cardiol. 2001;37(2, suppl A):319A.
52. Murakami T, Mizuno S, Ohsato K, et al. Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus. Am J Cardiol. 1999;84:92-94.
53. Collins AR, Meehan WP, Kintscher U, et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21:365-371.
54. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000;106:523-531.
55. Collins AR, Noh G, Hsueh WA, Law RE. PPARγ ligands attenuate angiotensin-II accelerated atherosclerosis in male low density receptor-deficient (LDLR-/-) mice [abstract]. Diabetes. 2001;50(suppl 2):A72.
56. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL, for the Pioglitazone 027 Study Group. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther. 2000;22:1395-1409.
57. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283:1695-1702.
58. Wolffenbuttel BHR, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabetes Med. 2000;17:40-47.
59. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001;111:10-17.
60. Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL, for the Troglitazone Triple-Therapy Study Group. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin: a multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:737-745.
61. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990;263:2893-2898.